Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI:10.1007/s11912-025-01639-5

Bhavesh Mohan Lal, Frits van Rhee, Samer Al Hadidi

{"title":"Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.","authors":"Bhavesh Mohan Lal, Frits van Rhee, Samer Al Hadidi","doi":"10.1007/s11912-025-01639-5","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to address the subgroup of patients with newly diagnosed multiple myeloma (NDMM) who have high-risk multiple myeloma (HRMM) and continue to experience poor outcomes despite recent therapeutic advances. We will explore various clinical, biochemical, imaging, genetic, and dynamic features associated with high-risk status, along with the different risk stratification tools developed to identify HRMM patients.Recent findings: Although numerous parameters for defining HRMM have been proposed, a universally accepted definition remains absent. Studies have shown diverse treatment responses and varying outcomes in HRMM patients, prompting the development of tailored therapeutic approaches. Emerging evidence supports the need for refined definitions and more targeted strategies to improve HRMM management. HRMM patients represent an unmet need in NDMM treatment, and a standardized definition for HRMM is crucial for advancing research and clinical care. This review discusses current and future treatment options, the necessity for a consistent HRMM definition, and the importance of clinical trials focused on this high-risk group to bridge existing treatment gaps.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"258-277"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01639-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review aims to address the subgroup of patients with newly diagnosed multiple myeloma (NDMM) who have high-risk multiple myeloma (HRMM) and continue to experience poor outcomes despite recent therapeutic advances. We will explore various clinical, biochemical, imaging, genetic, and dynamic features associated with high-risk status, along with the different risk stratification tools developed to identify HRMM patients.

Recent findings: Although numerous parameters for defining HRMM have been proposed, a universally accepted definition remains absent. Studies have shown diverse treatment responses and varying outcomes in HRMM patients, prompting the development of tailored therapeutic approaches. Emerging evidence supports the need for refined definitions and more targeted strategies to improve HRMM management. HRMM patients represent an unmet need in NDMM treatment, and a standardized definition for HRMM is crucial for advancing research and clinical care. This review discusses current and future treatment options, the necessity for a consistent HRMM definition, and the importance of clinical trials focused on this high-risk group to bridge existing treatment gaps.

查看原文本刊更多论文

高危多发性骨髓瘤的定义和治疗的证据现状。

综述目的：本综述的目的是针对新诊断的多发性骨髓瘤（NDMM）患者亚组，这些患者患有高风险多发性骨髓瘤（HRMM），尽管最近治疗取得了进展，但预后仍很差。我们将探讨与高危状态相关的各种临床、生化、影像学、遗传学和动态特征，以及开发用于识别HRMM患者的不同风险分层工具。最近的发现：尽管已经提出了许多定义HRMM的参数，但仍然没有一个普遍接受的定义。研究表明，在HRMM患者中，不同的治疗反应和不同的结果，促进了量身定制的治疗方法的发展。新出现的证据支持有必要改进定义和更有针对性的战略，以改善人力资源管理。HRMM患者代表了NDMM治疗中未满足的需求，HRMM的标准化定义对于推进研究和临床护理至关重要。本综述讨论了当前和未来的治疗方案，一致的HRMM定义的必要性，以及针对这一高危人群进行临床试验以弥补现有治疗差距的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.